|
|
Article: Neurocrine Biosciences Reports Positive Results From Second Phase III Clinical Trial With Indiplon in 200 Patients With Chronic Primary Insomnia; Indiplon Demonstrates Statistically Significant Improvement in Latency To Persistent Sleep (LPS) Throughout One Month of Treatment and Shows No Evidence Of Tolerance or Next Day Residual Effects.
- Article from:
- PR Newswire
- Article date:
- April 21, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. today announced positive results from the Company's second Phase III clinical trial with an immediate release formulation of indiplon, achieving statistically significant results in both primary and secondary endpoints of sleep initiation with no evidence of next day residual effects in 200 adult patients with Chronic Primary Insomnia. Results demonstrated that the immediate release formulation of indiplon was safe, well tolerated, and effective in these patients throughout the 35-day treatment period. The study was a randomized, double-blind, placebo- controlled, parallel group, multicenter Phase III clinical trial designed to assess the ...